Ensysce Biosciences, Inc. — Form SCHEDULE 13D/A

On August 5, 2026, Ensysce Biosciences entered into a merger agreement with Cy Biopharma, Inc., whereby Cy Biopharma will merge into Ensysce through a two-step merger structure. Simultaneously, Bob Gower (a significant shareholder) executed a support agreement committing to vote his shares in favor of required stockholder matters, including approval of issuance of Series C Non-Voting Convertible Preferred Stock to Cy Biopharma shareholders. Gower also holds a warrant to purchase 254,307 shares at $0.4840/share, exercisable through April 23, 2028. The merger agreement and support agreement are binding, with a 10-month expiration on the support commitment.